S
Santhoshi Bandla
Researcher at Thermo Fisher Scientific
Publications - 21
Citations - 2341
Santhoshi Bandla is an academic researcher from Thermo Fisher Scientific. The author has contributed to research in topics: Adenocarcinoma & Gene. The author has an hindex of 15, co-authored 20 publications receiving 2141 citations. Previous affiliations of Santhoshi Bandla include University of Rochester & Life Technologies.
Papers
More filters
Journal ArticleDOI
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
Austin M. Dulak,Petar Stojanov,Petar Stojanov,Petar Stojanov,Shouyong Peng,Shouyong Peng,Michael S. Lawrence,Cameron Fox,Chip Stewart,Santhoshi Bandla,Yu Imamura,Steven E. Schumacher,Steven E. Schumacher,Erica Shefler,Aaron McKenna,Scott L. Carter,Kristian Cibulskis,Andrey Sivachenko,Gordon Saksena,Douglas Voet,Alex H. Ramos,Daniel Auclair,Kristin Thompson,Carrie Sougnez,Robert C. Onofrio,Candace Guiducci,Rameen Beroukhim,Zhongren Zhou,Lin Lin,Jules Lin,Rishindra M. Reddy,Andrew C. Chang,Rodney Landrenau,Arjun Pennathur,Shuji Ogino,James D. Luketich,Todd R. Golub,Stacey Gabriel,Eric S. Lander,Eric S. Lander,Eric S. Lander,David G. Beer,Tony E. Godfrey,Gad Getz,Gad Getz,Adam J. Bass +45 more
Abstract: The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of ~15%, the identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole-exome sequencing of 149 EAC tumor-normal pairs, 15 of which have also been subjected to whole-genome sequencing. We identify a mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides. Statistical analysis of exome data identified 26 significantly mutated genes. Of these genes, five (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA) have previously been implicated in EAC. The new significantly mutated genes include chromatin-modifying factors and candidate contributors SPG20, TLR4, ELMO1 and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 identifies increased cellular invasion. Therefore, we suggest the potential activation of the RAC1 pathway as a contributor to EAC tumorigenesis.
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
Austin M. Dulak,Petar Stojanov,Petar Stojanov,Petar Stojanov,Shouyong Peng,Shouyong Peng,Michael S. Lawrence,Cameron Fox,Chip Stewart,Santhoshi Bandla,Yu Imamura,Steven E. Schumacher,Steven E. Schumacher,Erica Shefler,Aaron McKenna,Scott L. Carter,Kristian Cibulskis,Andrey Sivachenko,Gordon Saksena,Douglas Voet,Alex H. Ramos,Daniel Auclair,Kristin Thompson,Carrie Sougnez,Robert C. Onofrio,Candace Guiducci,Rameen Beroukhim,Zhongren Zhou,Lin Lin,Jules Lin,Rishindra M. Reddy,Andrew C. Chang,Rodney Landrenau,Arjun Pennathur,Shuji Ogino,James D. Luketich,Todd R. Golub,Stacey Gabriel,Eric S. Lander,Eric S. Lander,Eric S. Lander,David G. Beer,Tony E. Godfrey,Gad Getz,Gad Getz,Adam J. Bass +45 more
TL;DR: A mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides is identified and the potential activation of the RAC1 pathway is suggested as a contributor to EAC tumorigenesis.
Journal ArticleDOI
Gastrointestinal adenocarcinomas of the esophagus, stomach and colon exhibit distinct patterns of genome instability and oncogenesis
Austin M. Dulak,Steven E. Schumacher,Jasper van Lieshout,Yu Imamura,Cameron Fox,Byoungyong Shim,Alex H. Ramos,Gordon Saksena,Sylvan C. Baca,José Baselga,Josep Tabernero,Jordi Barretina,Peter C. Enzinger,Giovanni Corso,Franco Roviello,Lin Lin,Santhoshi Bandla,James D. Luketich,Arjun Pennathur,Matthew Meyerson,Shuji Ogino,Ramesh A. Shivdasani,David G. Beer,Tony E. Godfrey,Rameen Beroukhim,Adam J. Bass +25 more
TL;DR: Genomic features that were common and distinct to various gut-derived adenocarcinomas were defined, potentially informing novel opportunities for targeted therapeutic interventions and suggesting the potential use of genomic amplifications as biomarkers to guide therapy of gastric and esophageal cancers.
Journal ArticleDOI
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Daniel H. Hovelson,Andrew S. McDaniel,Andi K. Cani,Bryan Johnson,Kate Rhodes,Paul D. Williams,Santhoshi Bandla,Geoffrey Bien,Paul Choppa,Fiona Hyland,Rajesh Gottimukkala,Guoying Liu,Manimozhi Manivannan,Jeoffrey Schageman,Efren Ballesteros-Villagrana,Catherine S. Grasso,Michael J. Quist,Venkata Yadati,Anmol Amin,Javed Siddiqui,Bryan L. Betz,Karen E. Knudsen,Kathleen A. Cooney,Felix Y. Feng,Michael H. Roh,Peter S. Nelson,Chia Jen Liu,David G. Beer,Peter Wyngaard,Arul M. Chinnaiyan,Seth Sadis,Daniel R. Rhodes,Daniel R. Rhodes,Scott A. Tomlins +33 more
TL;DR: Through predefining somatic variants in solid tumors and compiling associated potential treatment strategies, OCP represents a simplified, broadly applicable targeted NGS system with the potential to advance precision oncology efforts.
Journal ArticleDOI
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors
Andi K. Cani,Daniel H. Hovelson,Andrew S. McDaniel,Seth Sadis,Michaela J. Haller,Venkata Yadati,Anmol Amin,Jarred V. Bratley,Santhoshi Bandla,Paul D. Williams,Kate Rhodes,Chia Jen Liu,Michael J. Quist,Daniel Rhodes,Catherine S. Grasso,Celina G. Kleer,Scott A. Tomlins +16 more
TL;DR: The genomic landscape underlying phyllodes tumor development is defined, potential molecular correlates to histologic grade are suggested, the spectrum of human tumors with frequent recurrent MED12 mutations is expanded, and IGF1R and EGFR are identified as potential therapeutic targets in malignant cases.